



*ASX Limited
Market Announcements Office*

Receipt of R&D Tax Incentive

8 November 2018, Melbourne: Australian drug delivery company, Phosphagenics Limited (ASX: POH, OTCQX: PPGNY), is pleased to announce that it has received part of its R&D Tax Incentive refund amounting to \$0.6m for the 2017-18 tax year. The partial receipt was due to amendments relating to prior year returns. A further \$0.2m is expected to be received before the end of the year.

The R&D tax refund relates to Australian R&D expenditure and eligible overseas expenditure on its injectable, opioid patch and other R&D programs.

Enquiries

Ms Anna Legg
Chief Financial Officer
Phosphagenics Limited
+61 3 9002 5000

About Phosphagenics

Phosphagenics Limited is focused on developing and commercialising innovative Human Health, Animal Health and Personal Care products using its proprietary drug delivery system called TPM[®] (Tocopheryl Phosphate Mixture). TPM[®] is derived from Vitamin E using a unique, proprietary and patented process and has been proven to enhance the solubility and oral, dermal and transdermal absorption of drugs and nutrients.

Amongst its major projects, Phosphagenics' is developing TPM[®] enhanced patches, gels and injectable products for the human health market and is also developing TPM[®] to enhance the feed efficiency and health of livestock.

Phosphagenics' shares are listed on the Australian Securities Exchange (POH) and its ADR – Level 1 program in the US is with The Bank of New York Mellon (PPGNY).

www.phosphagenics.com